AVELOX
LOE ApproachingNDAORALTABLET
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
AVELOX by Bayer is [see clinical pharmacology ()]. Approved for administration (), use in specific populations ()], acute bacterial sinusitis caused by streptococcus pneumoniae and 25 more indications. First approved in 1999.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVELOX (moxifloxacin) is a broad-spectrum fluoroquinolone antibiotic approved in 1999 for oral administration. It treats acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, complicated skin/soft tissue infections, and complicated intra-abdominal infections caused by various gram-positive and gram-negative pathogens. The drug inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial cell death.
LOE Approaching
Product approaching loss of exclusivity signals transition from growth-focused commercial operations to defensive positioning and potential cost-reduction initiatives.
Mechanism of Action
[see Clinical Pharmacology ()].
Worked on AVELOX at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.